Audeo Oncology (AURX) Files $60M IPO

Article Comments (0)

Audeo Oncology (Nasdaq: AURX) filed a $60 million IPO on form S-1 with the SEC after the close Friday. The company plans to list its common stock on The Nasdaq Global Market under the symbol "AURX."

Underwriters are Leerink Swann and Oppenheimer & Co.

Audeo Oncology is a late stage biopharmaceutical company primarily focused on utilizing our Hyaluronic Acid Chemotransport Technology, or HyACT, to target cancer drugs preferentially to tumor cells to enhance drug activity. HyACT is a flexible platform technology designed to increase the effectiveness of anti-cancer agents without increasing treatment toxicity. The company seek to reduce the risks related to drug development by using known anti-cancer drugs, and aim to enhance their commercial value by improving their effectiveness.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Friday's Hot IPOs Get Even Hotter (MKTO) (DATA)
• Tableau Software (DATA) IPO now indicated $45-$48
• PTC Therapeutics (PCTC) Files $85M IPO

Create E-mail Alert Related Categories

IPOs

Related Entities

S1

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?